Viridian Therapeutics, Inc.
NASDAQViridian Therapeutics just delivered one of its sharpest weekly moves of the year, gaining 25% to close at $23.59 — and the tension now is whether nearly 19% of the float sitting short will fuel more covering, or whether positioning resets around the new level. The catalyst is fresh. An earnings-linked event on August 6 produced an 12% single-day gain, and the stock added another…
Snapshot as of 20 Sept 2026
Viridian Therapeutics just delivered one of its sharpest weekly moves of the year, gaining 25% to close at $23.59 — and the tension now is whether nearly 19% of the float sitting short will fuel more covering, or…
Viridian Therapeutics heads into the summer with a striking contradiction at its core: options traders are the most bullish they have been in months, yet short sellers are quietly adding to one of the heaviest…
Viridian Therapeutics enters its May 7 earnings call riding one of the sharpest weekly moves in the biotech universe — up 38% in five sessions to $18.75, with a single-day gain of 33% on May 5 doing almost all the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VRDN — free to start on ORTEX.
Sign up for free →Open VRDN on ORTEX